Consun Pharmaceutical Group Limited (FRA:C1P)

Germany · Delayed Price · Currency is EUR

1.340

-0.050 (-3.60%)

At close: Jun 26, 2026

15.52% (1Y)

Market Cap	1.17B +10.6%
Revenue (ttm)	416.13M +15.2%
Net Income	131.27M +18.4%
EPS	0.15 +15.6%
Shares Out	n/a
PE Ratio	8.95
Forward PE	7.32
Dividend	0.04 (3.18%)
Ex-Dividend Date	Jun 9, 2026

Volume	n/a
Open	1.350
Previous Close	1.390
Day's Range	1.340 - 1.350
52-Week Range	1.050 - 2.180
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About FRA:C1P

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiol... [Read more]

Industry Pharmaceutical Preparations

Founded 1997

Employees 3,115

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol C1P

Financial Performance

In 2025, FRA:C1P's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY Financial Statements